统一针对基孔肯雅病毒的中和抗体测量方法：新型疫苗获批的前行之路？ - Suppr | 超能文献

Harmonising the measurement of neutralising antibodies against chikungunya virus: a path forward for licensing of new vaccines?

作者信息

Baylis Sally A, Knezevic Ivana, Almond Neil M

机构信息

Paul-Ehrlich-Institut, Langen 63225, Germany.

World Health Organization, Geneva, Switzerland.

出版信息

Lancet Microbe. 2024 Sep;5(9):100874. doi: 10.1016/S2666-5247(24)00097-1. Epub 2024 May 15.

DOI:10.1016/S2666-5247(24)00097-1

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Harmonising the measurement of neutralising antibodies against chikungunya virus: a path forward for licensing of new vaccines?统一针对基孔肯雅病毒的中和抗体测量方法：新型疫苗获批的前行之路？

Lancet Microbe. 2024 Sep;5(9):100874. doi: 10.1016/S2666-5247(24)00097-1. Epub 2024 May 15.

2

Development of Vaccines for Chikungunya Fever.基孔肯雅热疫苗的研发

J Infect Dis. 2016 Dec 15;214(suppl 5):S488-S496. doi: 10.1093/infdis/jiw271.

3

Humoral and cellular immune response to a single dose of a novel bivalent recombinant adenovirus-vector vaccine against West Nile virus and chikungunya virus in mice.小鼠对单剂量新型二价重组腺病毒载体西尼罗河病毒和基孔肯雅病毒疫苗的体液免疫和细胞免疫反应

Virol J. 2025 Jul 25;22(1):256. doi: 10.1186/s12985-025-02878-5.

4

Fighting back against chikungunya.抗击基孔肯雅热。

Lancet Infect Dis. 2015 May;15(5):488-9. doi: 10.1016/S1473-3099(15)70079-4. Epub 2015 Mar 2.

5

Amid Paraguay Chikungunya Outbreak, Vaccine Candidate Safe, Immunogenic.在巴拉圭基孔肯雅热疫情期间，候选疫苗安全且具有免疫原性。

JAMA. 2023 Jul 11;330(2):111. doi: 10.1001/jama.2023.10738.

6

Cross-neutralizing activity of the chikungunya vaccine VLA1553 against three prevalent chikungunya lineages.基孔肯雅疫苗VLA1553对三种流行的基孔肯雅病毒谱系的交叉中和活性。

Emerg Microbes Infect. 2025 Dec;14(1):2469653. doi: 10.1080/22221751.2025.2469653. Epub 2025 Mar 10.

7

Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.基于重组麻疹病毒的基孔肯雅疫苗的免疫原性、安全性和耐受性：一项随机、双盲、安慰剂对照、活性对照、首次人体试验。

Lancet Infect Dis. 2015 May;15(5):519-27. doi: 10.1016/S1473-3099(15)70043-5. Epub 2015 Mar 2.

8

Inactivated Viral Vaccine BBV87 Protects Against Chikungunya Virus Challenge in a Non-Human Primate Model.灭活病毒疫苗BBV87在非人灵长类动物模型中可抵御基孔肯雅病毒攻击。

Viruses. 2025 Apr 10;17(4):550. doi: 10.3390/v17040550.

9

A vaccine candidate based on baculovirus displaying chikungunya virus E1-E2 envelope confers protection against challenge in mice.基于杆状病毒展示的基孔肯雅病毒 E1-E2 包膜的疫苗候选物可在小鼠中提供针对挑战的保护。

J Virol. 2024 Nov 19;98(11):e0101724. doi: 10.1128/jvi.01017-24. Epub 2024 Oct 23.

10

Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice.二价嵌合病毒样颗粒和 DNA 疫苗共免疫诱导小鼠产生有前景的体液免疫应答。

Front Immunol. 2021 Mar 24;12:655743. doi: 10.3389/fimmu.2021.655743. eCollection 2021.

引用本文的文献

1

Chikungunya Virus Vaccines: A Review of IXCHIQ and PXVX0317 from Pre-Clinical Evaluation to Licensure.基孔肯雅病毒疫苗：从临床前评估到许可的 IXCHIQ 和 PXVX0317 综述。

BioDrugs. 2024 Nov;38(6):727-742. doi: 10.1007/s40259-024-00677-y. Epub 2024 Sep 18.